The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Malignant pheochromocytoma: current status and initiatives for future progress
Open accessAbstract
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th–18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multicenter studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Self-citationJOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
HOSKINS, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Self-citationBiochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Self-citationZerhouni, E. (2003) · Science · doi:10.1126/science.1091867 · Cited by 918
Thompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715
Trends in Endocrinology and Metabolism 1998
Brines, R. (1998) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(98)00013-7 · Cited by 699
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaître, X. (2003) · PubMed · Cited by 547
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
Cited by
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Self-citationGenetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Self-citationAmar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0709 · Cited by 450
Ayala-Ramirez, M., Feng, L., Johnson, M. M., Ejaz, S., Habra, M. A., Rich, T., Busaidy, N., Cote, G. J., Perrier, N., Phan, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1946 · Cited by 428
Metadata
- Authors
- Eisenhofer, G., Bornstein, S. R., Brouwers, F. M., Cheung, N.-K. V., Dahia, P. L., de Krijger, R. R., Giordano, T. J., Greene, L. A., Goldstein, D. S., Lehnert, H., Manger, W. M., Maris, J. M., Neumann, H. P. H., Pacak, K., Shulkin, B. L., Smith, D. I., Tischler, A. S., & Young, W. F.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2004-09
- Volume
- 11
- Issue
- 3
- Pages
- 423-436
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2131438124
- Cited by
- 338
- References
- 76
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.